![]() |
|
|
|||||||
|
Session 94
Poster Session
Osteopenia/Osteoporosis 4:30-6:30 pm 4E-F |
| 712-T. | Immunologic and Virologic Correlates of Bone Pathologies in HIV-Infection J. Fessel*1, L. Hurley2, S. Follansbee1, and D. Klein3 Kaiser Permanente Med. Care Prog., 1San Francisco, CA; 2Oakland, CA; and 3Hayward, CA
| ||
| 713-T. | Indinavir Administration Leads to Bone Loss in Mice M. W. H. Wang*, S. L. Teitelbaum, P. Tebas, W. G. Powderly, and F. P. Ross Washington Univ., St. Louis, MO
| ||
| 714-T. | HIV-1 Modulates TRANCE Expression in Vitro and in Vivo: Potential Mechanism for the Osteopenia of HIV Disease J. M. Fakruddin* and J. Laurence Weill Med. Coll. of Cornell Univ., New York, NY
| ||
| 715-T. | Bone Mineral Density, Lipodystrophy, and Bone Metabolism Markers in Treated and Not Treated HIV+ Patients C. Amiel*1, A. Ostertag2, E. Lajeunie3, L. Slama1, T. N. Guyen1, M. C. de Vernejou1, 2sup>, and W. Rozenbaum1 1Hosp. Rothschild; 2INSERM U349; and 3Hosp. Lariboisière, Paris, France
| ||
| 716-T. | Bone Loss Associated with Abnormalities in Glucose Metabolism in HIV Patients on Protease Inhibitors (PIs) T. Brown*, J. Timpone, M. Ruppe, R. Kassner, J. Pezzullo, P. Kumar, and T. Kehoe Georgetown Univ., Washington, DC
| ||
| 717-T. | Bone Mineral Density and Protease Inhibitor Use in Older HIV-Infected Women J. H. Arnsten*, R. Freeman, N. Santoro, H. Kunins, and E. E. Schoenbaum Montefiore Med. Ctr. and Albert Einstein Coll. of Med., Bronx, NY
| ||
| 718-T. | Longitudinal Evolution of Bone Mineral Density (BMD) and Bone Markers in HIV-Infected Individuals K. Mondy*, S. Lassa-Claxton, M. Hoffmann, K. Yarasheski, W. G. Powderly, and P. Tebas Washington Univ. Sch. of Med., St. Louis, MO
|